News | Breast Imaging | January 04, 2021

Deal further expands Hologic’s portfolio of world-class breast health solutions addressing the full continuum of care

Deal further expands Hologic’s portfolio of world-class breast health solutions addressing the full continuum of care

January 4, 2021 — Hologic, Inc. announced it has completed the acquisition of SOMATEX Medical Technologies GmbH, a leader in biopsy site markers and localization technologies, for approximately $64 million. The company was previously owned by E-Med Solutions GmbH, Berlin, a group of investors led by German private equity company Westlake Partners.

The transaction supports Hologic’s strategy to provide a comprehensive suite of innovative solutions across the continuum of breast health care. Specifically, SOMATEX’s differentiated products will enable Hologic to strengthen and further expand its breast marker portfolio, which has been growing consistently. As a result of the acquisition, Hologic will also enhance its sales presence in Europe by expanding its direct channel in Germany and its network of regional and international distributor partners.

“The acquisition of SOMATEX allows us to expand our biopsy portfolio by providing a suite of market-leading solutions that not only address our customers’ needs, but also improve the biopsy experience for their patients,” said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions. “We’ve had a strong partnership with SOMATEX for several years, which along with our shared focus on innovation, will allow us to quickly integrate and begin building a pipeline that will drive profitable growth and recurring revenue for our breast health business globally.”

SOMATEX specializes in the development and manufacturing of minimally invasive devices in the areas of tumor diagnostics, biopsy and interventional specialties, providing Hologic with additional expertise and capabilities to continue to grow its breast health portfolio. The SOMATEX product portfolio includes the Tumark® family of tissue markers, which were distributed by Hologic in the U.S. prior to the acquisition.

“For years, SOMATEX has been committed to driving innovative, best-in-class tumor marker and localization solutions for our customers and their patients and to becoming a leader in our space,” said Joerg Heise, Managing Director of SOMATEX. “ We are excited to continue this journey through Hologic and their global footprint, providing so many more with access to these pioneering technologies that aid in the early detection and treatment of breast cancer.”

SOMATEX is expected to generate approximately $13 million of revenue in calendar 2020, including sales of Tumark markers to Hologic. The acquisition is expected to be slightly accretive to Hologic's non-GAAP earnings per share starting in the Company’s current fiscal year.

For more information: www.hologic.com


Related Content

News | RSNA

December 1, 2023 — The Society of Breast Imaging (SBI) announced that Elizabeth Morris, MD, has been selected as the SBI ...

Time November 30, 2023
arrow
News | RSNA

November 30, 2023 — Hologic, Inc. showcased several recent developments in next-generation AI solutions at the 109th ...

Time November 30, 2023
arrow
News | RSNA

November 30, 2023 — Breast cancer mortality is significantly reduced when women regularly attend screening mammograms ...

Time November 30, 2023
arrow
News | Breast Imaging

November 29, 2023 — A deep learning artificial intelligence (AI) model that was developed using only mammogram image ...

Time November 29, 2023
arrow
News | Artificial Intelligence

November 28, 2023 — iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, and ...

Time November 28, 2023
arrow
News | RSNA

November 28, 2023 — iCAD, Inc., a global medical technology company developing cancer-detection solutions, will present ...

Time November 28, 2023
arrow
News | Breast Imaging

November 27, 2023 — Barco announces introduction of the DL Precise AI software in addition to the current Intuitive ...

Time November 27, 2023
arrow
Feature | RSNA

November 27, 2023 — The collective anticipation of the radiology community was palpable from early morning through ...

Time November 27, 2023
arrow
News | RSNA

November 22, 2023 — ScreenPoint Medical has announced that its Transpara breast AI has surpassed 5 million mammograms ...

Time November 22, 2023
arrow
News | FDA

November 22, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...

Time November 22, 2023
arrow
Subscribe Now